{"id":"NCT02525861","sponsor":"Baxalta now part of Shire","briefTitle":"GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study","officialTitle":"A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-08","primaryCompletion":"2020-07-29","completion":"2020-07-29","firstPosted":"2015-08-18","resultsPosted":"2021-10-14","lastUpdate":"2021-10-14"},"enrollment":34,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alpha1-antitrypsin Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"GLASSIA","otherNames":["Alpha1-Proteinase Inhibitor","A1PI"]}],"arms":[{"label":"Cohort I: GLASSIA (High-end)","type":"EXPERIMENTAL"},{"label":"Cohort II: GLASSIA (Low-end)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is 2-fold: (1) to evaluate the safety and potential immunogenicity of GLASSIA following intravenous (IV) administration via in-line filtration; and (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 milligrams per kilogram (mg/kg) Body weight (BW)/week active alpha1-proteinase inhibitor (A1PI) protein for 25 weeks in participants with emphysema due to congenital A1PI deficiency.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution","timeFrame":"From start of study treatment up to Week 26","effectByArm":[{"arm":"Cohort I: GLASSIA (High-end)","deltaMin":0,"sd":null},{"arm":"Cohort II: GLASSIA (Low-end)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":18},"commonTop":["Nasopharyngitis","Diarrhoea","Upper respiratory tract infection","Back pain","Dyspnoea"]}}